- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.09. | Aktis raises $175M to fuel radiopharma drug development | ||
| 30.09. | Prime to narrow gene editing research as it strikes deal with Bristol Myers | ||
| 30.09. | Key factors shaping the future of clinical services organizations in the APAC market | ||
| 30.09. | Accelerating precision oncology: The value of an end-to-end partner for therapeutic access | ||
| 27.09. | J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers | ||
| 27.09. | FDA, after delay, clears Regeneron and Sanofi drug for COPD | ||
| 27.09. | Bristol Myers schizophrenia drug, the first of its kind, approved by FDA | ||
| 26.09. | Pfizer to pull sickle cell drug from market, shut down trials | ||
| 26.09. | Arch raises another $3B biotech fund in pursuit of 'coolest' new science | ||
| 26.09. | BioAge prices $198M IPO, validating pivot to obesity drug research | ||
| 25.09. | An Italian biotech gets $52M to advance pediatric gene therapies | ||
| 25.09. | Struggling 2Seventy scraps a key cancer study | ||
| 25.09. | Amgen claims success for two immune drugs, but results underwhelm Wall Street | ||
| 25.09. | Novo CEO pressed by Senate to cut prices of obesity, diabetes drugs | ||
| 24.09. | Bluebird to lay off another 25% of workforce in latest restructuring | ||
| 24.09. | Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal | ||
| 24.09. | Biogen, UCB get the lupus data they've waited two decades for | ||
| 23.09. | AstraZeneca, Daiichi's Enhertu successor faces more questions after latest stumble | ||
| 23.09. | After setback, Biohaven to seek approval of neurological disorder drug | ||
| 23.09. | Streamlining IND applications for cell and gene therapy innovations | ||
| 23.09. | Data advancements are finally unlocking drug safety during pregnancy | ||
| 23.09. | The golden era of GLP-1 drugs: Where we are and what comes next | ||
| 23.09. | Startup Vicebio banks $100M in bid to make 'cost-effective' vaccines | ||
| 20.09. | FTC sues major pharmacy benefit managers over insulin prices | ||
| 20.09. | Novo sinks on obesity drug results; Sanofi reveals anticipated MS data |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
